Back to Search
Start Over
Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2017 Sep 01; Vol. 56 (17), pp. 2321-2324. Date of Electronic Publication: 2017 Aug 10. - Publication Year :
- 2017
-
Abstract
- Crizotinib, which is effective in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer, is sometimes associated with the generation of complex renal cysts. A 56-year-old man with ALK positive adenocarcinoma received crizotinib. Ten months after the introduction of crizotinib, a cystic lesion developed from his right kidney to the iliopsoas muscle, accompanied by fever, anemia, and hypoproteinemia. After 17 months of treatment, crizotinib was switched to alectinib, followed by the recovery of hypoproteinemia and systemic inflammation. Switching to alectinib may be beneficial in patients demonstrating crizotinib-associated complex renal cysts with systemic inflammation and exhaustion.
- Subjects :
- Antineoplastic Agents therapeutic use
Carbazoles therapeutic use
Carcinoma, Non-Small-Cell Lung pathology
Crizotinib
Humans
Lung Neoplasms pathology
Male
Middle Aged
Piperidines therapeutic use
Pyrazoles therapeutic use
Pyridines therapeutic use
Treatment Outcome
Adenocarcinoma drug therapy
Carcinoma, Non-Small-Cell Lung drug therapy
Kidney Diseases, Cystic chemically induced
Kidney Diseases, Cystic drug therapy
Lung Neoplasms drug therapy
Protein Kinase Inhibitors therapeutic use
Pyrazoles adverse effects
Pyridines adverse effects
Receptor Protein-Tyrosine Kinases therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 56
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 28794366
- Full Text :
- https://doi.org/10.2169/internalmedicine.8445-16